Could Your GLP-1 Be Lowering Your Breast Cancer Risk Too?
- 2 days ago
- 4 min read
By Daryl & Jen, Pacific Northwest Medical Group — Medical Weight Loss in Puyallup & Federal Way, WA. Published June 2026.
Hey everyone –
Short version: A big new study out of Penn Medicine looked at more than 110,000 women and found the ones taking a GLP-1 were about 30% less likely to develop breast cancer. And here's the part that got my attention — that protection held up even after the researchers matched women by weight and diabetes status. So this looks like more than "just" the weight loss. (Original research article at the bottom of my summary, as always.)
This one really lit up my engineering brain. We already talk about what these meds do for your weight, blood sugar, heart, knees, even how fast your body ages. But cancer prevention? That's a big one — and breast cancer hits close to home for so many of the women in our clinic.
What the Penn Medicine study actually found
Researchers at Penn's Abramson Cancer Center, led by Dr. Elizabeth McDonald, pulled the health records of 111,646 women ages 45 to 80 who'd had breast imaging. About 15,000 of them were on a GLP-1 (the same family as the Semaglutide and Tirzepatide so many of you take); the rest were not.
Here's how the numbers landed:
In the full group: 35% lower odds of a new breast cancer diagnosis in the GLP-1 users.
In a tighter, "apples-to-apples" comparison — where they carefully matched each GLP-1 user to a similar non-user by age, race, breast density, BMI, and diabetes status — the benefit was still about 30% lower odds.
The findings were presented at the 2026 ASCO Annual Meeting (the big national cancer conference) and published the same day in JCO Oncology Practice. This isn't a fringe report — it's a serious team at a major cancer center.
Why the "matched" number is the interesting part
Here's the piece I love. We've long known that carrying extra weight — especially after menopause — raises breast cancer risk, so you'd expect a weight-loss med to help just by trimming pounds. That part's almost obvious.
But the researchers matched women who had similar BMIs and the same diabetes status, and the GLP-1 users still came out ~30% lower. Translation: two women at the same weight, one on a GLP-1 and one not — the GLP-1 user had meaningfully lower odds. That suggests something beyond the weight loss itself may be at work.
The leading theory? These meds calm the chronic, low-grade inflammation that quietly drives a lot of disease, plus they have metabolic and even epigenetic effects that may make it harder for tumors to get going. Same theme we keep seeing across the research — these drugs do more under the hood than move the scale.
I'll be straight with you, like always
This was an observational study — it shows a strong link, not absolute proof that the medication caused the lower risk. It didn't track which specific GLP-1 women took or for how long, and a real gold-standard clinical trial hasn't been done yet. The good news: Dr. McDonald's team is already working to launch one, including for women at high risk of breast cancer.
So nobody's calling this a cancer cure, and nobody should stop their mammograms — screening still matters, full stop. But a possible 30% lower risk of breast cancer, on top of everything else these meds do? That's a win we'll take.
It's one more reason hitting your goal weight isn't the finish line — it's where a lot of the good stuff really starts. Keep going. And if a woman in your life needs to hear this, send it her way.
Stay healthy everyone!
–Daryl and Jen
Frequently Asked Questions
Do GLP-1 medications lower breast cancer risk? In a 2026 Penn Medicine study of over 110,000 women, those taking a GLP-1 were about 30% less likely to be diagnosed with breast cancer. The study was observational, so it shows a strong association rather than proof of cause, and a clinical trial is being planned.
Is the lower risk just because of the weight loss? Not entirely, it appears. When researchers matched women by BMI and diabetes status, GLP-1 users still had roughly 30% lower odds — suggesting effects beyond weight loss, likely including reduced inflammation.
Which medications were involved? GLP-1 receptor agonists — the drug class that includes semaglutide and tirzepatide. The study didn't break results down by specific medication or length of use.
Should I stop breast cancer screening if I'm on a GLP-1? No. This research is promising but early, and it is not a substitute for mammograms or MRI. Keep up with the screening your doctor recommends.
Where can I start medically supervised semaglutide or tirzepatide near me? Pacific Northwest Medical Group offers physician-supervised GLP-1 weight loss programs at our Puyallup and Federal Way, Washington clinics, with free consultations.
About the authors
Daryl and Jen run Pacific Northwest Medical Group, a physician-supervised medical weight loss clinic with locations in Puyallup and Federal Way, Washington. The clinic has guided over 1,150 patients through GLP-1 treatment (semaglutide and tirzepatide) paired with nutrition coaching, 3D body-composition scanning, and ongoing medical support. Daryl writes these research summaries from both a clinical and personal perspective — he's on the journey too.
Book Your FREE Consultation
Ready to start — or stay the course? No contract, no membership fees, just real medical support.
Puyallup: (253) 340-2270 — 6622 112th St E, Puyallup, WA 98373Federal Way: (253) 363-8877 — 1814 S 324th Pl, Federal Way, WA 98003 🌐 www.pnwmedicalgroup.com
Real Support, Real Results, Real Transformations.
Sources
Penn Medicine, "GLP-1 use linked to lower breast cancer incidence in large cohort study," June 2, 2026 — https://www.pennmedicine.org/news/glp-1-use-linked-to-lower-breast-cancer-incidence
McDonald, E. et al., JCO Oncology Practice (2026) — https://ascopubs.org/doi/10.1200/OP-26-00485
2026 ASCO Annual Meeting, Abstract 10506 — https://www.asco.org/abstracts-presentations/260663
This article is for general education and is not a substitute for individual medical advice, breast cancer screening, or treatment. Pacific Northwest Medical Group prescribes compounded semaglutide and tirzepatide prepared by a licensed 503A compounding pharmacy. These are not FDA-approved products. They are prescribed on a patient-specific basis when clinically appropriate.
